Phase 2 N=52 A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy
Non-Small Cell Lung Cancer
Primary: Non-Progression Rate (NPR) at 8 Weeks — 41.4; 65.2 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=132 Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia
Lip and Oral Cavity Cancer · Oral Leukoplakia · Oropharyngeal Cancer
Primary: Relative Percent Change in Total Lesion Area After 6 Months on Study — -20.6; -17.1 percentage change
Phase 2 N=273 A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy
Arthritis, Rheumatoid
Primary: Percentage of Participants With American College of Rheumatology 20 (ACR 20) Response at Week 28 — 40.0; 52.7; 54.5; 44.4 percentage of participants — p=0.184
Phase 2 N=41 Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
Melanoma (Skin)
Primary: Evaluation of Objective Clinical Response (CR/PR/SD) — 0; 0; 1; 2 participants
Phase 2 N=76 A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels
Ejaculatory Dysfunction · Hypogonadism
Primary: Change From Baseline in the Male Sexual Health Questionnaire-Ejaculatory Dysfunction-Short Form (MSHQ-EjD-SF) Ejaculatory Function Score at 16 Weeks — 3.61; 2.95 units…
Phase 3 N=14,840 Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
Cervical Cancer · Vulvar Cancer · Vaginal Cancer
Primary: Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (Test of Hypothesis) — 0.5; 15.8 Cases per 10,000 person-years follow-up — p=<0.0001
Phase 2 N=40 Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant
Recurrent Chronic Hepatitis C Virus · Post Liver Transplant
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 70.0 percentage of participants
Phase 4 N=16 Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia
Tachycardia, Ventricular
Primary: Inhibition of Idiopathic Ventricular Tachycardia
Phase 3 N=393 A Study of Duloxetine in Fibromyalgia
Fibromyalgia
Primary: Change From Baseline to 14-Week Endpoint in the BPI 24-Hour Average Pain Severity Item of the BPI-Modified Short Form Score (MMRM) — -1.90; -1.58 units on a scale…
Phase 3 N=300 Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country
Japanese Encephalitis
Primary: SCRs (Seroconversion Rate) as Defined by Percentage of Subjects With Plaque Reduction Neutralization Test Titers of>1:10 at 1 Month After the Booster Dose — 100; 100…
Phase 3 N=250 Stepped Care to Optimize Pain Care Effectiveness
Pain
Primary: Brief Pain Inventory (Pain) — 3.57; 4.59 units on a scale
Phase 1 N=9 Safety and Efficacy Study of Peripheral Blood Mononucleated Cells for Treatment of Liver Cirrhosis
Liver Cirrhosis
Primary: Number of Participants With Severe Adverse Events — 0; 0; 0 participants
Phase 4 N=38 Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells
Hypertension
Primary: Pulse Wave Velocity (Measure of Arterial Stiffness) — 9.4; 8.9 meters per second (m/s)
N/A N=32 Split Thickness Donor Site Healing With MIST Study
Burns · Trauma · Venous Ulcers
Primary: Rate of Wound Healing — 12.1; 21.3 Days
N/A N=40 Maximal Bruce Protocol With the Use of Regadenoson For Myocardial Perfusion Stress Testing
Cardiac Function
Primary: Number of Participants With Side Effects, Including Dyspnea, Headache, Dizziness, Chest Pain, Nausea, Abdominal Discomfort, Dysgeusia, Flushing, and Symptomatic…